Skip to main content
. 2013 Oct 8;123(11):4755–4768. doi: 10.1172/JCI65698

Figure 7. DPP-3 and TOP-1 control CD8+ T cell priming in vivo.

Figure 7

(A) B78OVA-FTheat cells (2 × 106) were mixed with recombinant TOP-1 or DPP-3 and injected into mice on days 0 and 2, and Ag-specific immune responses were analyzed on day 7. Data are from 3 experiments (n = 3 per group). (B) NT2.5-FTheat cells (5 × 106), mixed with recombinant TOP-1 or with B78-FT cells (1 × 107), were injected into mice on days 0, 2, and 4, and Ag-specific immune responses were analyzed on day 7. Data show 1 representative of 3 independent experiments (n = 3 per group). (C) Subcutaneously growing control or TOP-1 shRNA–transfected EG7 tumors were exposed to X-ray radiation (15 Gy), and Ag-specific immune responses were analyzed after 5 days. Data are from 2 experiments (n = 3 per group). *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test.